Literature DB >> 20691599

Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1.

Régis Barattin1, Thomas Perrotton, Doriane Trompier, Doriane Lorendeau, Attilio Di Pietro, Amaury du Moulinet d'Hardemare, Hélène Baubichon-Cortay.   

Abstract

The multidrug resistance protein 1 (MRP1), involved in multidrug resistance (MDR) of cancer cells, was found to be modulated by verapamil, through stimulation of GSH transport, leading to apoptosis of MRP1-overexpressing cells. In this study, various iodinated derivatives of verapamil were synthesized, including iodination on the B ring, known to be involved in verapamil cardiotoxicity, and assayed for the stimulation of GSH efflux by MRP1. The iodination, for nearly all compounds, led to a higher stimulation of GSH efflux. However, determination of concomitant cytotoxicity is also important for selecting the best compound, which was found to be 10-fold more potent than verapamil. This will then allow us to design original anti-cancer compounds which could specifically kill the resistant cancer cells. Copyright 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691599     DOI: 10.1016/j.bmc.2010.07.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

2.  Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Authors:  Nathalia Daflon-Yunes; Flavio Eduardo Pinto-Silva; Raphael Silveira Vidal; Bruna Fortunato Novis; Tandressa Berguetti; Raphael Rodrigues Soares Lopes; Carla Polycarpo; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

3.  ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.

Authors:  Charlotte Gauthier; Csilla Ozvegy-Laczka; Gergely Szakacs; Balazs Sarkadi; Attilio Di Pietro
Journal:  Front Pharmacol       Date:  2013-11-07       Impact factor: 5.810

Review 4.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

5.  PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells.

Authors:  Huan-Huan Lv; Chen-Xiao Zhen; Jun-Yu Liu; Peng Shang
Journal:  Acta Pharmacol Sin       Date:  2020-03-04       Impact factor: 6.150

6.  MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor.

Authors:  Chiara Riganti; Roberta Giampietro; Joanna Kopecka; Costanzo Costamagna; Francesca Serena Abatematteo; Marialessandra Contino; Carmen Abate
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.